Member Webinar : Hemophilia Alliance Hosts – A Webinar from Takeda – Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances

Date: Thursday, March 12th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:

Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances.

OBJECTIVE:

After this webinar, participants will be able to:

1. Describe the clinical impact and risk factors for FVIII inhibitor development in Previously Untreated Patients (PUPs)
2. Summarize key findings from past PUP studies, including the SIPPET trial
3. Review Phase 3 PUP trial data for rurioctocog alfa pegol
4. Discuss implications for monitoring and managing inhibitor risk in current clinical practice

AUDIENCE:

All HTC Staff.

SPEAKERS:

Caitlin Montcrieff, MSN, CPNP – Director, US Medical Hematology & Rare Disease

Robert Sidonio, MD, MSc

Dr. Robert F. Sidonio, Jr, MD, MSc is a Professor of pediatrics at Emory University School of Medicine and the Medical Director of the Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders of Emory. Dr. Sidonio’s clinical and research interests are in the management of pediatric patients with bleeding disorders. His research focus has included women with bleeding disorders, von willebrand disease and the study of inhibitor development in patients with Hemophilia A. Dr. Sidonio was the principal investigator for the Phase 3 clinial trial of rurioctocog alfa pegol in previously untreated patients with Hemophilia A.